Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 12,601–12,700 of 15,747
Codon Optimality Modulates Cellular Stress and Innate Immune Responses Triggered by Exogenous RNAs
Seephetdee, C., Bejar, N., Castillo, K., Chau, E. P., Nguyen, T. Y., Godin, B., & Kiss, D. (2026) · Journal of Molecular Biology · doi:10.1016/j.jmb.2026.169995 · Cited by 1
Translational research on pandemic virus infection using nonhuman primate models
Ishigaki, H., & Itoh, Y. (2025) · Virology · doi:10.1016/j.virol.2025.110511 · Cited by 2
Stærke, N. B., Reekie, J., Johansen, I. S., et al. (2022) · medRxiv · doi:10.1101/2022.10.09.22280886 · Cited by 1
Humoral and cellular responses to SARS-CoV-2 vaccination in patients with lymphoid malignancies
(2021) · doi:10.1101/2021.12.08.21266760 · Cited by 1
“SARS-CoV-2 vaccination has been shown to be highly efficacious in preventing symptomatic COVID-19 disease in healthy individuals (Polack et al., 2020; Ramasamy et al., 2021).”
BackgroundNakayama, T., Ito, T., Ishiyama, R., & Katayama, K. (2023) · Vaccines · doi:10.3390/vaccines11111677 · Cited by 2
Wineinger, N. E., Li, V., Waalen, J., & Topol, E. J. (2021) · medRxiv · doi:10.1101/2021.03.11.21252708 · Cited by 1
Taste Detection Threshold in Relation to Pfizer COVID-19 Vaccine
Abbas, S. Q., & Zaidan, T. F. (2023) · Cureus · doi:10.7759/cureus.33786 · Cited by 1
“Understanding the pathophysiological mechanisms is still lacking [19].”
BackgroundmRNA Vaccines for Influenza: Hope for a Universal Vaccine?
Omotara, P., Zhu, W., & Wang, B. (2026) · BioDrugs · doi:10.1007/s40259-026-00791-z · Cited by 2
“Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines have proven highly effective at reducing viral transmission, as demonstrated by the reduction in SARS-CoV-2 cases during the coronavirus disease 2019 (COVID-19) pandemic [22–24].”
RNA-Based COVID-19 vaccine candidates with clinical phase trials in progress
Al, L. İ. R., SÖNMEZER, M. Ç., & Ünal, S. (2021) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2104-139 · Cited by 1
“Besides, it was found effective in the advanced age group, similar to those in the younger age group [10].”
Self-citationLarpparisuth, N., Pongsakornkullachart, K., Ratchawang, N., Vongwiwatana, A., & Skulratanasak, P. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e42291 · Cited by 1
Rare but Severe Cardiovascular Complications of SARS-CoV-2 Vaccination: A Call for Awareness
Marchetta, M., Golino, M., Markley, J. D., & Abbate, A. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001740 · Cited by 1
Piera, X. M. I., Campo-Montoya, R. D., Cuadrado‐Tejedor, M., García‐Osta, A., Garbayo, E., & Blanco‐Prieto, M. J. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2587903 · Cited by 6
“Given the success of vaccines such as those from Pfizer [44] and Moderna [45], built on the prior approval of the siRNA formulation Patisiran (Onpattro) [46],”
The future of tumor vaccines in the post‐COVID‐19 era—Current challenges
CHRISTOPOULOS, P. F. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.521 · Cited by 1
Bazin, R., Rochette, S., Perreault, J., Fournier, M., Grégoire, Y., Boivin, A., Lewin, A., Germain, M., & Renaud, C. (2022) · medRxiv · doi:10.1101/2022.08.15.22278798 · Cited by 1
Feng, S., Huang, M., Quan, Y., Sun, L., Lin, J., Zhang, D., Wei, X., Wang, Z., Ma, X., Wang, S., et al. (2025) · Virology · doi:10.1016/j.virol.2025.110612 · Cited by 1
(2022) · doi:10.1101/2022.07.21.22277903 · Cited by 1
“The rapid development and administrative deployment of effective vaccines has played an extremely vital role in minimizing and mitigating the global burden of the pandemic [15, 16].”
BackgroundMultiple Sclerosis Onset before and after COVID-19 Vaccination: Can HLA Haplotype Be Determinant?
Bianco, A. D., Sante, G. D., Colò, F., Arcangelis, V. D., Cicia, A., Giacomo, P. D., Bonis, M. D., Morganti, T., Carlomagno, V., Lucchini, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084556 · Cited by 2
“The first vaccines available were mRNA vaccines and included BNT162b2–Comirnaty© (two intramuscular injections 21 days apart) [71] and mRNA-1273—Spikevax© (two intramuscular injections 28 days apart) [72].”
BackgroundReacciones cutáneas a la vacuna Pfizer-BioNTech contra COVID-19. Una experiencia ecuatoriana
Chérrez-Ojeda, I., Robles‐Velasco, K., Osorio, M. F., et al. (2022) · Revista Alergia México · doi:10.29262/ram.v69i1.973 · Cited by 1
Vaccine hesitancy in the time of COVID: How to manage a public health threat
Lane, H. C., & Gordon, S. M. (2024) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.91a.24062 · Cited by 4
COVID-19 Vaccine hesitancy and influencing factors: An example from Turkey
Sarımehmet, D., SARIMEHMET, Y. K., Altınbaş, B. C., & ARDIÇ, C. (2024) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.40.4.7979 · Cited by 1
“22 However, it is known that vaccines are widely recognized as a highly effective and optimal strategy for mitigating the substantial disease burden experienced around the world.”
BackgroundSuzuki-Okutani, M., Okamura, S., Tanggis, Sasaki, H., Lee, S. P., Yoshida, A., Goto, S., Matsumoto, M., Yamawaki, M., Miyazaki, T., et al. (2025) · eLife · doi:10.7554/elife.97532.2 · Cited by 4
Obesity and its Relationship with Covid-19: A Review of the Main Pharmaceutical Aspects
Hodel, K. V. S., Fonsêca, A. F., Barbosa, I. A. B., Medina, C., Alves, B. K. A. M. D. F., Maciel, C. A. D. O., Nascimento, D., Oliveira-Junior, G. S., Pedreira, L. A., de Souza, M., et al. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010264503231108070917 · Cited by 2
DNA-terminus-dependent transcription by T7 RNA polymerase and its C-helix mutantsPreprint
Yu, B., Chen, Y., Yan, Y., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.12.07.570323 · Cited by 1
Kadowaki, T., Irie, S., Takahashi, Y., et al. (2022) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.134.86 · Cited by 1
A review on RNA technologies renaissance: a paradigm shift shaping the future of modern medicine
Singh, S. P., Mundlia, P., Sharma, A. M., Kaur, H., Chaubey, B., Khajuria, A., Chatterjee, M., Jaiswal, P. K., Ranawat, P., Singh, G., et al. (2026) · Next Bioengineering · doi:10.1016/j.nxbio.2026.100016 · Cited by 1
SARS-CoV-2 infection in adults and HIV: an update
Bousis, D., Mulita, F., Marlafeka, I., Paraskevas, T., & Velissaris, D. (2022) · Medicinski Glasnik · doi:10.17392/1440-21 · Cited by 1
Implementation and Adherence to Regular Asymptomatic Testing in a COVID-19 Vaccine Trial
Williams, L. R., Emary, K., Phillips, D., Hay, J., Larwood, J. P. J., Ramasamy, M., Pollard, A., Grassly, N., & Voysey, M. (2024) · medRxiv · doi:10.1101/2024.02.28.24303505 · Cited by 2
Lin, T. H., Keowmani, T., & Moon, T. M. (2024) · Malaysian Journal of Medical Sciences · doi:10.21315/mjms2024.31.3.10 · Cited by 2
“Both of which are recognised as major allergenic or immunogenic excipients (34–36).”
BackgroundVaccine Mandates: Weighing the Common Good vs Personal Conscience and Autonomy
Jones-Nosacek, C. (2023) · The Linacre Quarterly · doi:10.1177/00243639231213515 · Cited by 5
Wasserstrum, Y., Nadav, S., Segev, A., et al. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101084 · Cited by 1
“Both mRNA-based agents, BNT162b2 (Pfizer\BioNTech) and mRNA-1273 (Moderna) have been reported to cause myocarditis or pericarditis [4 – 6].”
Tuyls, S., van der Brempt, X., Faber, M. A., Gadisseur, R., Dezfoulian, B., Schrijvers, R., & Froidure, A. (2021) · Acta Clinica Belgica · doi:10.1080/17843286.2021.1909447 · Cited by 2
Sasankan, S., Gathers, D., Bellerose, A., Pankratz, V. S., & Tawfik, B. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127091 · Cited by 1
Synergetic measures to contain highly transmissible variants of SARS-CoV-2Preprint
Su, H., Cheng, Y., Witt, C. C., Ma, N., & Pöschl, U. (2021) · medRxiv · doi:10.1101/2021.11.24.21266824 · Cited by 1
“S5 [2], Pmask,a = P0,a(1 − m) 2 + Psc,am(1 −m) + Pwp,am(1 −m) + Pum,am 2 (S5)”
BackgroundMethodInfluentialMaternal COVID-19 Disease and COVID-19 Immunization
Sunder, A., Varghese, B., Taha, O. E., Keshta, M. S., Bughamar, A. K., Mohamed, E. N. A., Fadhulalla, Y. M. A., & Darwish, B. (2022) · Cureus · doi:10.7759/cureus.28328 · Cited by 1
“(2020) showed that two doses of the BioNTech/Pfizer BNT162b2 mRNA vaccine gave 95% protection against COVID-19 in the non-pregnant age group of 16 years or more [13].”
BackgroundHussain, H., Ganesh, A., Milane, L. S., & Amiji, M. M. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2189697 · Cited by 1
Delayed injection-site reactions caused by COVID-19 vaccine: COVID arm.
Matsudate, Y. (2021) · 日本臨床皮膚科医会雑誌 · doi:10.3812/jocd.38.754 · Cited by 1
Cpg 684: An Effective Adjuvant for the Inactivated COVID-19 Vaccine in Mice
Liu, J., Cang, T., Jiang, C., Li, K., Liu, S. J., Wang, H., Wang, M., Chen, Y., Shao, Y., & Liu, J. (2023) · Future Virology · doi:10.2217/fvl-2022-0172 · Cited by 1
Case Report: An immunocompromised, vaccine breakthrough COVID-19 patient with pneumonia
Patrinos, A., Komninos, D., Dimouli, K., Kartsonakis, A., Serpanos, D., Kalogeropoulos, G., & Dimitropoulou, D. (2021) · F1000Research · doi:10.12688/f1000research.53089.1 · Cited by 1
Guest, J. D., Zhang, Y., Flores, D., Atkins, E., Ren, K., Caì, Y., Rosenthal, K., Wang, Z., Kim, K., Chen, C. H., et al. (2025) · Vaccines · doi:10.3390/vaccines13080778 · Cited by 1
“Several vaccines have been licensed, utilizing mRNA [2,3], adenovirus [4], and recombinant protein [5] technologies, with seasonal boosters to accommodate new variants.”
Pawlicka, A., Wężyk, K., Matwiej, K., et al. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16389 · Cited by 1
Two doses of the Pfizer-BioNTech vaccine, two different side effects: Skin and eye
Gedık, B., Erol, M. K., Bulut, M., et al. (2022) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2022.02.020 · Cited by 1
Superficial thrombophlebitis in ipsilateral breast after COVID-19 vaccination
Aran, S., Kayder, O. O., Chopra, T., & Abujudeh, H. H. (2022) · Radiology Case Reports · doi:10.1016/j.radcr.2022.05.018 · Cited by 1
“[9] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al.”
Klose, A. M., Kosoy, G., & Miller, B. L. (2023) · PLoS ONE · doi:10.1371/journal.pone.0277846 · Cited by 3
“The standard deviation of serum samples was calculated from replicate probe spots on each array [21].”
MethodWada, T. T., Yokota, K., Sakai, S., Soma, M., Kajiyama, H., Tarumoto, N., Maesaki, S., Maeda, T., Nagata, M., & Mimura, T. (2022) · Modern Rheumatology Case Reports · doi:10.1093/mrcr/rxac052 · Cited by 1
“A multinational, placebo-controlled, observer-blinded, pivotal efficacy trial showed that the BNT162b2 mRNA vaccine was 95% effective in preventing COVID-19 7 days after the second dose [1].”
BackgroundFrei, J., Eisel, D., Jarzębska, N. T., Mellett, M., Yener, I. G., Abdou, M. T., Gouttefangeas, C., Flatz, L., Diken, M., Kündig, T. M., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01738-z · Cited by 3
Self-citationVentura-Enríquez, Y., la Rosa, E. C.-D., Díaz-Padilla, E., Murrieta, S., Segundo-Martínez, S., Fernández-Sánchez, V., & Vargas‐De‐León, C. (2024) · Viruses · doi:10.3390/v16040551 · Cited by 1
“Different health authorities worldwide have developed and approved several vaccines for application [1].”
BackgroundZare, M., Mirahmadizadeh, A., Khosravi, M., Karimi, M., & Dehghani, S. L. (2023) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.37.99 · Cited by 1
“In the current survey, similar side effects were reported that were also consistent with those reported in phase III clinical trials (13, 14).”
ResultZoughbor, S. H., Rasbi, Z. A., Yousif, A., Ameri, M. A., Hussein, M. M., Hourani, M. S., Khamis, S. M., Ansari, H., Syed, I., Balaraj, K. S., et al. (2023) · Case Reports in Oncology · doi:10.1159/000529913 · Cited by 1
Mammalian cells-based platforms for the generation of SARS-CoV-2 virus-like particles
(2023) · doi:10.1101/2023.07.24.550415 · Cited by 1
“95% effectiveness for the BNT162b2 mRNA 51 COVID-19 vaccine (Pfizer-BioNTech) [6], 94.”
BackgroundSong, Z., Luo, Q., Wan, L., Zhu, Q. K., Liu, R., Yin, X., Lu, X., Wei, L., Xiang, Z., & Zou, Y. (2023) · Vaccines · doi:10.3390/vaccines11020442 · Cited by 1
“To date, 11 vaccines have been included in the World Health Organization emergency use list, mainly including: (1) Two mRNA-based vaccines expressing full spike (S) glycoprotein, BNT162b2 (by Pfizer) and mRNA-1273 (by Moderna), with clinical trial data showing that BNT162b2 and mRNA-1273 were 95% [1] and 94.”
MethodSmart Nanostructured Materials for SARS-CoV-2 and Variants Prevention, Biosensing and Vaccination
Wang, L., & Li, Z. (2022) · Biosensors · doi:10.3390/bios12121129 · Cited by 1
Altomare, N., & Cohen, D. A. (2022) · EMJ Diabetes · doi:10.33590/emjdiabet/21-00263 · Cited by 1
Atarashi, Y., Kim, J., Irino, Y., Amano, M., Tsuchiya, K., Maeda, K., Terada, M., Iwamoto, N., Shimada, S., Mitsuya, H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-94317-2 · Cited by 1
“This study included COVID-19 convalescent individuals 18 and COVID-19 vaccinated individuals without a previous history of COVID-19 in earlier studies conducted at the National Center for Global Health and Medicine (NCGM), Tokyo, Japan.”
InfluentialSingh, A. K., Kaur, S. P., Shahanshah, M. F. H., Sharma, B., Chaudhary, V. K., Gupta, S., & Gupta, V. (2022) · Wiley eBooks · doi:10.1002/9781119789741.ch22 · Cited by 1
Shaffer, A. M., & Meyerowitz, E. A. (2025) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2025.02.002 · Cited by 1
Hartvigsen, G., & Dimitroff, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0325129 · Cited by 2
“This approximates evidence that, for instance, the BNT162b2 vaccine (BioNTech/Pfizer) efficacy, compared to a placebo control, may not be observed until 12 days after being administered [20,21].”
Steps towards licensure of self-amplifying RNA vaccines
Wilbrink, M. F., Herfst, S., & de Vries, R. D. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00593-0 · Cited by 1
Apple, F. S., Bothwell, B., Koti, J., Bauer, W., Dwyer, R., Chen, H., Wu, H., Li, P., Lindgren, B., Gottlieb, S., et al. (2022) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfac053 · Cited by 1
Self-citationFairlamb, M. S., Kumru, O. S., Hickey, J. M., Elbaz, N. M., Bevernaegie, R., Straeten, A. V., Vandekerckhove, K., Ingham, D. J., Neuenswander, S. A., Douglas, J. T., et al. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104199 · Cited by 1
Vaccine effectiveness against the B.1.617.2 in the intensive care unit
Koc, I., Ozmen, S. U., & Deniz, O. (2023) · Medicine · doi:10.1097/md.0000000000035588 · Cited by 1
“[6] Other reports confirmed effectiveness among healthcare workers.”
Weng, S.-H., Yen, Y., Cheng, F.-S., Chou, Y.-C., & Hu, H. (2024) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.05.006 · Cited by 1
Nicolas, A., Sannier, G., Dubé, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4189020 · Cited by 1
Alshahrani, M. (2023) · Chapman University Digital Commons (Chapman University) · doi:10.36837/chapman.000491 · Cited by 1
Antibody responses after BNT162b2 vaccination in Japanese geriatric intermediate care facilities
Suita, A., Ohfuji, S., Kasamatsu, A., Kondo, K., Nakata, H., Kita, T., Deguchi, A., Fujimoto, M., Iba, K., Sakamoto, H., et al. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100412 · Cited by 1
“To control the COVID-19 pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines were rapidly developed, demonstrating ≥ 90 % efficacy for preventing SARS-CoV-2 infection in clinical trials [11].”
BackgroundLarsen, S. E., Erasmus, J. H., Reese, V. A., Pecor, T., Archer, J. F., Kandahar, A., Hsu, F., Reed, S. G., Baldwin, S. L., & Coler, R. N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.23.481669 · Cited by 1
Akther, S., Samiha, F., Sony, S. A., Haque, M. A., Hasnat, M. A., Islam, S. M. S., Ahmed, S., & Abdullah-Al-Shoeb, M. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1435930 · Cited by 2
“Recent mRNA vaccines, such as BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna-NIAID), have given adequate defense against severe COVID-19 infection (22, 23).”
An Evaluation of Serological Tests to Determine Postvaccinal Immunity to SARS-CoV-2 by mRNA Vaccines
García, G. I., Rodríguez, Á. D., Fernández, B. D., Estrada, C. C., Ferreiro, T. G., García, N. C., & Seco‐Calvo, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247534 · Cited by 1
Al‐Obaidi, A. H., Majeed, M., & Al‐Qaseer, A. H. A. M. (2026) · Health Science Reports · doi:10.1002/hsr2.71768 · Cited by 1
“Results from large efficacy trials indicate the BNT162b2 vaccine was effective in over 90% of symptomatic cases [14].”
A community effort to discover small molecule SARS-CoV-2 inhibitorsPreprint
Schimunek, J., Seidl, P., Elez, K., Hempel, T., Le, T., Noé, F., Olsson, S., Raich, L., Winter, R., Gökcan, H., et al. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-1d5w8 · Cited by 2
Ramadan, M. N., Davidovski, F. S., Espersen, C., Al‐Rubai, A. H., Khoraizat, A., Johansen, N. D., Skaarup, K. G., Lassen, M. C. H., Hviid, A. P., Grove, T., et al. (2025) · Open Heart · doi:10.1136/openhrt-2025-003584 · Cited by 3
Reopening California: Seeking Robust, Non-Dominated COVID-19 Exit Strategies
de Lima, P. N., Lempert, R. J., Vardavas, R., Baker, L., Ringel, J., Rutter, C. M., Ozik, J., & Collier, N. T. (2021) · RAND Corporation eBooks · doi:10.7249/wra1080-2 · Cited by 2
Pantha, B., Mohammed-Awel, J., & Vaidya, N. K. (2023) · Mathematical Medicine and Biology A Journal of the IMA · doi:10.1093/imammb/dqad007 · Cited by 2
Gravetz, A., Tennak, V., Mezhebovsky, V., et al. (2021) · Transplantology · doi:10.3390/transplantology2040041 · Cited by 1
“A two-dose regimen of BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) was shown to confer 95% protection against COVID-19 in persons 16 years of age or older [14].”
BackgroundÁvila‐Nieto, C., Vergara‐Alert, J., Amengual-Rigo, P., Ainsua‐Enrich, E., Brustolin, M., de la Concepción, M. L. R., Pedreño-López, N., Rodon, J., Urrea, V., Pradenas, E., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291972 · Cited by 2
Invited Editorial: Characteristics and outcomes of adverse events following COVID‐19 vaccination
Bouland, A. J., & March, J. A. (2021) · Journal of the American College of Emergency Physicians Open · doi:10.1002/emp2.12566 · Cited by 1
A Case of Diabetic Chorea Secondary to Appetite Loss Due to COVID-19 Vaccination
Inoue, H., Kusano, E., Shinkai, Y., et al. (2023) · Cureus · doi:10.7759/cureus.49138 · Cited by 1
“However, mRNA vaccines have a higher frequency of local and systemic adverse reactions than conventional vaccines [10,11], which poses a challenge.”
BackgroundBeata, K., Katarzyna, S., Julia, B., et al. (2023) · doi:10.22541/au.168871685.50181209/v1 · Cited by 1
Izumi, N., Furukawa, Y., Kinoshita, S., Ishii, M., Goto, A., Yasuda, H., Ando, J., Nakauchi, H., & Ando, M. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1772146 · Cited by 1
“SARS-CoV-2 mRNA vaccines are globally used and administered periodically, making them an extremely accessible and safe source of T-cell receptor (TCR) stimulation (Berthaud et al., 2024; Polack et al., 2020).”
Ray, D., Quijano, R., & Andricioaei, I. (2021) · bioRxiv · doi:10.1101/2021.08.13.456317 · Cited by 4
Early tolerability of Comirnaty vaccine in patients with chronic neurological diseases
Budowski, C., Zavanone, C., Thivard, L., et al. (2021) · Revue Neurologique · doi:10.1016/j.neurol.2021.05.005 · Cited by 1
“In our study, a two-dose regimen of Comirnaty/BNT162b2 vaccine (30 mg per dose, given 28 days apart) was found to be safe in a brief follow-up period after the administration with even better tolerability than those found in the phase 2/3 trial assessing the safety, immunogenicity and efficacy of the vaccine [5].”
BackgroundMethodResultInfluentialDetection of SARS-CoV-2 by Mass Spectrometry
Wandernoth, P., Kriegsmann, K., Kriegsmann, J., et al. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2111-0_12 · Cited by 1
Tilch, K., Pütz, S. M., Mitrov, L., Stecher, M., Appel, K., Pilgram, L., Geisler, R., Scherer, M., Vehreschild, J. J., Kraus, M., et al. (2025) · Asian Journal of Ethics in Health and Medicine · doi:10.51847/8qhncsofqh · Cited by 1
Consequences of COVID-19 vaccine allocation inequity in ChicagoPreprint
Zeng, S., Pelzer, K. M., Gibbons, R. D., et al. (2021) · medRxiv · doi:10.1101/2021.09.22.21263984 · Cited by 1
Efectos adversos de las vacunas frente al SARS-CoV-2 en farmacéuticos comunitarios de Pontevedra
Rodríguez, N. F. A., Fornos-Pérez, J. A., Domínguez, I. B., Mera-Gallego, R., García-Rodríguez, P., Carrera-Pérez-de-Juan, M. D., León-Rodríguez, L., Mera-Gallego, I., & Ferradanes, A. A. (2022) · Farmacéuticos Comunitarios · doi:10.33620/fc.2173-9218.(2022/vol14).003.03 · Cited by 1
Modelling the SARS-CoV-2 vaccination campaign in Italy: the fundamental role of unreported cases
Traini, M. C., & Caponi, C. (2022) · IJID Regions · doi:10.1016/j.ijregi.2022.02.006 · Cited by 1
Kitano, H. (2025) · Springer eBooks · doi:10.1007/978-981-96-8066-5_1 · Cited by 1
Ikrar, T., Muchsin, W., & Sophian, A. (2026) · Research Square · doi:10.21203/rs.3.rs-9109248/v1 · Cited by 2
The Risk-Benefit Balance in the COVID-19 “Vaccine Hesitancy” Literature: An Umbrella Review ProtocolPreprint
Chaufan, C., Hemsing, N., McDonald, J., & Heredia, C. (2023) · SocArXiv (OSF Preprints) · doi:10.31235/osf.io/c3j2f · Cited by 1
Nanotechnology in vaccines and personalized medicine
Azevedo, M. S. P., & Patri, A. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824010-6.00043-5 · Cited by 1
Zhang, Y., Yuan, J., Wu, A., Wang, Z., Ni, R., Yan, K., Liang, X., He, T., Gu, M., Meng, C., et al. (2026) · Veterinary Microbiology · doi:10.1016/j.vetmic.2026.110930 · Cited by 1
Faits saillants sur des vaccins contre la COVID-19
Kolber, M. R., Fritsch, P., Price, M., Singer, A. G., Young, J. C., Dugré, N., Bradley, S., & Nickonchuk, T. (2021) · Canadian Family Physician · doi:10.46747/cfp.6703e82
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.